Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of... Clin Drug Investig (2017) 37:873–879 DOI 10.1007/s40261-017-0547-7 ORIGINAL RESEARCH ARTICLE Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men 1 1 1,2 1 ˚ • • • • Hakan Olsson Niclas Petri Lars Erichsen Anders Malmberg Lars Grundemar Published online: 28 June 2017 The Author(s) 2017. This article is an open access publication Abstract Results Time-matched, one-sided 95% upper confidence Background and Objectives Degarelix is a gonadotropin- boundaries for baseline-corrected average changes from releasing hormone antagonist registered for the treatment placebo for the QT interval, corrected using the Fridericia of advanced hormone-dependent prostate cancer. Treat- method (DDQTcF), did not exceed 10 ms at any timepoint, ment causing androgen deprivation is associated with QT with maximum degarelix concentrations reaching approx- prolongation and this study investigated whether degarelix imately threefold the concentrations seen in the treatment at supratherapeutic concentrations has an intrinsic effect of prostate cancer. Furthermore, concentration-exposure per se on cardiac repolarisation and the QT interval. analysis indicated absence of any QT prolongation effects Methods This was a single-centre, randomised, crossover of degarelix. No significant effect on any http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Drug Investigation Springer Journals

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men

Loading next page...
 
/lp/springer_journal/effect-of-degarelix-a-gonadotropin-releasing-hormone-receptor-TllYK0AAtw
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
1173-2563
eISSN
1179-1918
D.O.I.
10.1007/s40261-017-0547-7
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial